These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38768713)

  • 1. DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice.
    Shen X; Wang S; Hao Y; Fu Y; Ren L; Li D; Tang W; Li J; Chen R; Zhu M; Wang S; Liu Y; Shao Y
    Virol Sin; 2024 Jun; 39(3):490-500. PubMed ID: 38768713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
    Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
    Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
    Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X
    Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
    Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
    Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model.
    Bodmer BS; Fiedler AH; Hanauer JRH; Prüfer S; Mühlebach MD
    Virology; 2018 Aug; 521():99-107. PubMed ID: 29902727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice.
    Li E; Yan F; Huang P; Chi H; Xu S; Li G; Liu C; Feng N; Wang H; Zhao Y; Yang S; Xia X
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31968702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV.
    Almansour I; Jermy BR
    Hum Vaccin Immunother; 2024 Dec; 20(1):2346390. PubMed ID: 38691025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
    Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
    Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice.
    Veit S; Jany S; Fux R; Sutter G; Volz A
    Viruses; 2018 Dec; 10(12):. PubMed ID: 30558354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection.
    Jia W; Channappanavar R; Zhang C; Li M; Zhou H; Zhang S; Zhou P; Xu J; Shan S; Shi X; Wang X; Zhao J; Zhou D; Perlman S; Zhang L
    Emerg Microbes Infect; 2019; 8(1):760-772. PubMed ID: 31130102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
    Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
    Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice.
    Li E; Chi H; Huang P; Yan F; Zhang Y; Liu C; Wang Z; Li G; Zhang S; Mo R; Jin H; Wang H; Feng N; Wang J; Bi Y; Wang T; Sun W; Gao Y; Zhao Y; Yang S; Xia X
    Viruses; 2019 Aug; 11(9):. PubMed ID: 31470645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
    Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G
    J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
    Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
    Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates.
    Zhan Y; Deng Y; Huang B; Song Q; Wang W; Yang Y; Dai L; Wang W; Yan J; Gao GF; Tan W
    Vaccine; 2019 Apr; 37(15):2122-2130. PubMed ID: 30851967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.
    Wirblich C; Coleman CM; Kurup D; Abraham TS; Bernbaum JG; Jahrling PB; Hensley LE; Johnson RF; Frieman MB; Schnell MJ
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
    Tang J; Zhang N; Tao X; Zhao G; Guo Y; Tseng CT; Jiang S; Du L; Zhou Y
    Hum Vaccin Immunother; 2015; 11(5):1244-50. PubMed ID: 25874632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.